Immunomodulators and delivery systems for vaccination by mucosal routes.
Current paediatric immunization programmes include too many injections in the first months of life. Oral or nasal vaccine delivery eliminates the requirement for needles and can induce immunity at the site of infection. However, protein antigens are poorly immunogenic when so delivered and can induce tolerance. Novel ways to enhance immune responses to protein or polysaccharide antigens have opened up new possibilities for the design of effective mucosal vaccines. Here, we discuss the immunological principles underlying mucosal vaccine development and review the application of immunomodulatory molecules and delivery systems to the selective enhancement of protective immune responses at mucosal surfaces.
Ryan
E J
EJ
Institute of Immunology, National University of Ireland, Maynooth, Co., Kildare, Ireland.
Daly
L M
LM
Mills
K H
KH
D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D016503:Drug Delivery Systems; D006801:Humans; D009092:Mucous Membrane; D014612:Vaccines / Q000008:administration & dosage*
D000276:Adjuvants, Immunologic; D014612:Vaccines